EpiCombi.AI
EpiCombi.AI uses machine learning to design multi-targeted drugs that address the complexity of cancer by leveraging genomic signatures. The company generates AI-derived, network-acting therapeutic hypotheses by combining genomics-driven signatures with computational network biology and predictive models. It operates as a biotechnology therapeutics developer applying proprietary ML and systems-biology approaches to discover multi-target small molecules and combinations. The company is an Oxford University spinout focused initially on oncology but with applicability to other disease areas. EpiCombi.AI positions itself within the drug discovery and biotech category working with preclinical development partners and research collaborators.
EpiCombi.AI
EpiCombi.AI uses machine learning to design multi-targeted drugs that address the complexity of cancer by leveraging genomic signatures. The company generates AI-derived, network-acting therapeutic hypotheses by combining genomics-driven signatures with computational network biology and predictive models. It operates as a biotechnology therapeutics developer applying proprietary ML and systems-biology approaches to discover multi-target small molecules and combinations. The company is an Oxford University spinout focused initially on oncology but with applicability to other disease areas. EpiCombi.AI positions itself within the drug discovery and biotech category working with preclinical development partners and research collaborators.